Pfizer Italiana is taking over the Italian company Bioindustria Farmaceutici. Under a preliminary agreement between the US firm and the Caraccia family (owners of BF), all of BF's pharmaceutical operations in both the prescription and over-the-counter sectors, will in time be ceded to Pfizer, along with the sales network.
The deal specifically excludes workforce cuts. Initially, BF will operate under a production agreement with Pfizer. Subsequently, a new firm, Bioindustria Lim, will be formed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze